Table 2.

Currently Available Level of Evidence for the 12 Reviewed PROMs

	I	II	III	IV-V
NEI VFQ-25		Substantial evidence in RCTs and population-based studies for late-stage clinical DRD
IVI		Evidence in clinical and population-based samples
RetDQoL			CS with mostly clinical samples
DR-U			CS in a large clinical sample
RetCAT		CS in a large clinical sample
EQ-5D/VAS			CS with mostly clinical samples
SF-6D			CS with mostly clinical samples
HUI3			CS with mostly clinical samples
VisQoL			CS with mostly clinical samples
TTO/SG			CS with mostly clinical samples

CS = cross-sectional; DRD = diabetic retinal disease; DR-U = Diabetic Retinopathy Utility instrument; EQ-5D = European Quality of Life Questionnaire; HUI-3 = Health Utilities Index; IVI = Impact of Vision Impairment; NEI VFQ-25 = National Eye Institute 25-item Visual Function Questionnaire; PROM = patient-reported outcome measure; RCT = randomized controlled trial; RetCAT = Diabetic Retinopathy and Macular Edema Computerized Adaptive Test; RetDQoL = Retinopathy Dependent Quality of Life questionnaire; SF-6D = Short Form 6-D; SG = standard gamble; TTO = time trade-off; VAS = visual analog scale; VisQoL = Vision and Quality of Life index.